A Phase 1b/2 Trial of Liposomal Cytarabine and Daunorubicin (CPX-351) in Intermediate to High-Risk Acute Myeloid Leukemia for Patients Who Have Failed an Initial Cycle of Induction Chemotherapy

A Phase 1b/2 Trial of Liposomal Cytarabine and Daunorubicin (CPX-351) in Intermediate to High-Risk Acute Myeloid Leukemia for Patients Who Have Failed an Initial Cycle of Induction Chemotherapy

Introduction Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy with a high rate of recurrence following standard chemotherapy that continues to have a poor prognosis. While there have been numerous recent advances in the treatment of AML, seven days of continuous infusion cytara...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2023-11, Vol.142 (Supplement 1), p.5946-5946
Hauptverfasser: Pontious, Corbin, Garzon, Ramiro, Blachly, James S., Blaser, Bradley Wayne, Choe, Hannah, Grieselhuber, Nicole R., Long, Meixiao, Vasu, Sumithira, Wall, Sarah A, Larkin, Karilyn T., Eisfeld, Ann-Kathrin, Koenig, Kristin L, Sahasrabudhe, Kieran D, Sanchez-Petitto, Gabriela, Saad, Ayman, Bhatnagar, Bhavana, Lyberger, Justin, Borate, Uma M., Mims, Alice, Jonas, Brian A., Behbehani, Gregory K
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Introduction Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy with a high rate of recurrence following standard chemotherapy that continues to have a poor prognosis. While there have been numerous recent advances in the treatment of AML, seven days of continuous infusion cytarabine combined with three doses of an anthracycline medication (7+3) remains the most common backbone treatment for younger (
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2023-184344